stat6

STAT6-IN-2 (Comp R-84) is a STAT6 inhibitor that effectively reduces the secretion of the chemokine eotaxin-3, which induces eosinophil infiltration. This compound is valuable for studying immune diseases [1].

AS1517499 is a blood-brain barrier permeable inhibitor of STAT6 phosphorylation (IC50= 21 nM).

AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions.

STAT6-IN-8 is a highly selective STAT6 inhibitor (IC50=0.25 μM)that exerts potent anti-inflammatory and anti-allergic effects by blocking STAT6’s DNA-binding activity and its dimerization process. STAT6-IN-8 can be used in research on STAT6-related diseases such as atopic dermatitis, bronchial asthma, and allergic rhinitis.

STAT6-IN-9 is a highly potent STAT6 inhibitor with an EC₅₀ of 4 nM. It markedly blocks STAT6 activation mediated by the IL-13/IL-13 receptor/IL-4 receptor pathway and inhibits CCL17 secretion with an IC₅₀ of 4.6 nM. STAT6-IN-9 is suitable for studying various chronic inflammatory diseases related to the STAT6 signaling pathway, including allergic diseases, asthma, and chronic obstructive pulmonary disease.

STAT6-IN-10 is a highly active signal transducer and activator of transcription 6 (STAT6) inhibitor with an EC₅₀ of 0.002 μM. It inhibits the secretion of CCL17 in human peripheral whole blood with an IC₅₀ of 0.095 μM and can be used in research on skin diseases and respiratory disorders.

STAT6-IN-11 is a STAT6 inhibitor with an EC₅₀ of 6 nM. It inhibits the secretion of CCL17 in human peripheral whole blood with an IC₅₀ of 83 nM through the IL-13–IL-13 receptor/IL-4 receptor pathway and can be used in research on skin diseases and respiratory diseases.

(trans)-STAT6 modulator-5 (Compound 95) is a modulator of the STAT6 protein, inhibiting the STAT6 signaling pathway. This compound holds potential for the research of inflammatory diseases and allergic reactions.

PROTACSTAT6 degrader-1 (Compound I-2) is a STAT6 PROTAC degrader with a DC50 of less than 1 nM. This compound is utilized in the study of inflammation and cancer.

STAT6ligand-1 is a ligand for STAT6. It can be utilized in the synthesis of PROTACs, such as STAT6degrader-2.

STAT6ligand-1 is a ligand for STAT6. It can be used in the synthesis of PROTACs, such as Compound 22.

PROTACSTAT6 degrader-2 is a potent PROTAC degrader targeting STAT6. It exhibits a DC50 of 1-10 nM for STAT6 in human peripheral blood mononuclear cells (PBMC) and a DC50 of less than 100 nM in HEK293-HIBiT-STAT6 cells. PROTACSTAT6 degrader-2 is applicable for the treatment of diseases mediated by STAT6.

STAT6-IN-5 (example 84) is an inhibitor of STAT6 (IC50 = 0.24 μM), applicable for investigating inflammation and allergies such as atopic dermatitis.

STAT6-IN-4 (compound 78) is a STAT6 inhibitor with an IC₅₀ of 0.34 μM, suitable for investigating inflammatory and allergic diseases.

STAT6degrader-3 (I-1) is a STAT6 degrader with a degradation concentration (DC50) of less than 1 nM.

STAT6-IN-7 (Compound 178) is a STAT6 inhibitor with an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. It is utilized in research related to inflammation and allergic diseases.

STAT6-IN-1, a STAT6 inhibitor, exhibits high affinity for the SH2 domain of STAT6 (IC 50 = 0.028 µM), making it suitable for research on allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease, or cancer.

STAT6-IN-3 (Compound 18a) is an inhibitor of STAT6, targeting the Src Homology 2 (SH2) domain with an IC50 value of 44 nM. It is used in research on inflammatory disorders, such as asthma [1].

SD-436 is a selective and highly efficient STAT3 PROTAC degrader (DC50 = 0.5 μM), with an IC50 of 19 nM for STAT3, significantly higher than for STAT1/4/5/6. SD-436 depletes STAT3 and induces tumour regression in mouse leukaemia and lymphoma xenograft models.

YM-341619 (AS1617612) is a potent, orally active STAT6 inhibitor (IC50: 0.70 nM) that inhibits IL-4-induced Th2 differentiation in mouse splenic T cells with an IC50 value of 0.28 nM, without affecting Th1 cell differentiation. YM-341619 holds potential for research into allergic diseases, such as allergic asthma.

Febuxostat 67M-1 is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and reduces the risk of gout or kidney stone formation.

Febuxostat 67M-4 is a derivative compound of Febuxostat 67M-1 which is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and reduces the risk of gout or kidney stone formation.

Febuxostat 67M-2 is a derivative of Febuxostat 67M-1, which is a xanthine oxidase inhibitor. Febuxostat 67M-2 reduces the production of uric acid in the body and is used to lower the risk of gout or kidney stones.

AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells (DC50=1 nM) and depletes STAT6 proteins in mouse tissues, which can be used in cancer research.